Research peptides vs prescription peptides: are “research use only” peptides legal?

The difference in one table

FDA’s 2026 warning letters to peptide sellers

On August 24, 2026, FDA’s drug centre sent warning letters to five sellers after reviewing their websites in July 2026. The letters call the listed products unapproved new drugs and treat the bacteriostatic water sold alongside them as a drug too. Earlier letters in 2026 went to three more sellers.

Tesamorelin appears in all five August letters. The GLP-1s — semaglutide, tirzepatide and the unapproved retatrutide — appear in almost all of them. None of the eight letters named BPC-157 or TB-500.

Why the “research use only” label does not work

FDA addressed the disclaimer directly. In its letter to Royal Peptides it wrote: “Despite statements on your product labeling marketing your products ‘for research use only’ and ‘not for human or animal consumption,’ evidence obtained from your website establishes that your products are intended to be drugs for human use” (FDA). Selling dosing calculators, injection supplies or before-and-after claims next to a “not for human use” line is the kind of evidence FDA relies on.

What you give up with a research product

A research-use vial comes with no prescription, no named pharmacy, no sterility or potency testing you can verify and no clinician watching for side effects. FDA has written that BPC-157 raises questions about “peptide-related impurities and active pharmaceutical ingredient (API) characterization” even when a pharmacy makes it; a website with no pharmacy at all offers less assurance still. See peptide safety.

The lawful route, and its limits

The lawful route is a licensed clinician and a licensed pharmacy. That route exists for approved products like Egrifta WR and for Category 1 substances like NAD and glutathione. For BPC-157, TB-500, CJC-1295 and ipamorelin it does not yet exist: no category, no bulks-list entry and no approval. A clinic that says otherwise should show you the legal basis in writing. See which peptides can be compounded and how to verify a provider.

October 2026: what changed

• April 2026 — Category 2 withdrawals. FDA moved BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, injectable GHK-Cu and other peptides off its Category 2 list after the nominators withdrew them. FDA lists them as “nominated but withdrawn” (page current as of April 22, 2026). They were not moved into Category 1.
• July 23–24, 2026 — advisory committee. FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. FDA staff proposed not adding BPC-157 or TB-500. A law-firm account reports the committee voted 8–6 (one abstention) to recommend BPC-157, KPV and TB-500 (McDermott, July 27, 2026). A vote is advice; FDA has taken no final action.
• October 14–15, 2026 — interim access policy under White House review. The OIRA review site lists “Interim Access Policy for Compounding Using Certain Peptides” from HHS/FDA (RIN 0910-ZD94, stage: Notice), received October 14, 2026 and pending review; no text has been published (reginfo.gov). Reuters reported the filing on October 15 (Reuters), and the AP, citing two people, said it would let pharmacies make some popular peptides, including BPC-157. Which peptides, on what terms and from when are not public. Our running table: peptide legal status 2026.

For research sellers: even if the interim access policy is published and lets pharmacies compound some peptides, it would cover pharmacies, not research-chemical websites. FDA’s August letters show it is enforcing against those sellers now.

New this month: what is known about FDA’s peptide interim access policy · a status table for 16 peptides (FDA and WADA).